Adult refractory nephrotic syndrome
Conditions
Interventions
experimental group:Rituximab treatment
contol group: routine regimen
Sponsors
???
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as primary nephrotic syndrome (MCD, IMN, FSGS); 2. Patients older than 18 years old; 3. EGFR > 40ml / min, urinary protein > 3.5g/d; 4. In patients who received traditional treatment for at least 3 months (glucocorticoid, immunosuppressant CNI (tacrolimus or cyclosporine A), ACEI), the urinary protein decreased by less than 50%.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of RTX use; 2. Patients with hepatitis B, hepatitis C, HIV, etc; 3. Patients allergic to the drug or mouse protein; 4. Patients with severe active infection; 5. Patients with severe impairment of immune response (such as hypogammaglobulinemia, severe CD4 or CD8 cell count reduction); 6. Patients with severe heart failure (NYHA grade IV); 7. Those who are pregnant, nursing, or using unreliable methods of contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease remission; | — |
Countries
China
Contacts
Public ContactQijun Wan
Department of Endocrinology, Shenzhen Second People’s Hospital,
Outcome results
None listed